The role of Pneumococcal vaccine

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 4, 2008, Pages 608-615

  Braido, Fulvio ^a   Bellotti, Michele ^a   De Maria, Andrea ^a,b   Cazzola, Mario ^c   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Airway pathologies; COPD; Pneumonia; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ARTHRALGIA; ASTHENIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COST; DISEASE EXACERBATION; DRUG EFFICACY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; LYMPHADENOPATHY; MORBIDITY; MORTALITY; MYALGIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VACCINATION;

HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STREPTOCOCCUS PNEUMONIAE;

EID: 47049123187     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.04.001     Document Type: Review

References (64)

1. Lee T.A., Weaver F.M., and Weiss K.B. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 22 1 (2007) 62-67
2. Talbot T.R., Hartert T.V., Mitchel E., et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 352 (2005) 2082-2090
3. Nielsen S.V., and Henrichsen J. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark. Epid Infect 117 3 (1996) 411-416
4. Fedson D.S., Musher D.M., et al. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices ACIP. Morbidity Mortality Wkly Rep 46 RR-8 (1997) 1-24
5. Fedson M.S., and Musher D.M. Pneumococcal vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed (1999), WB Saunders, Philadelphia
6. Metlay J.P., Hofmann J., Cetron M.S., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30 3 (2000 Mar) 520-528
7. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Publ Health 90 2 (2000 Feb) 223-229
8. Javaloyas M., Garcia-Somoza D., and Gudiol F. Epidemiology and prognosis of bacteremia: a 10-y study in a community hospital. Scand J Infect Dis 34 6 (2002) 436-441
9. Afessa B., Greaves W.L., Frederick W.R., et al. Pneumococcal bacteriemia in adults:a 14-year study in a n inner-city universty hospital. Clin Infect Dis 21 2 (1995 Aug) 345-351
10. Balakrishnan I., Crook P., Morris R., et al. Early predictors of mortality in pneumococcal bacteraemia. J Infect 40 3 (2000 May) 256-261
11. Reinert R.R., Reinart S., Van der Linden M., et al. Antimicrobial susceptibility of pneumococcus in eight European countries. Antimicrob Agents Chemother 49 7 (2005) 2903-2913
12. Marchese A., Ardito F., Fadda G., et al. The sentinel project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Hemophilus in Italy. Int J Antimicrob Agents 26 1 (2005) 8-12
13. Miravitlles M., et al. Update to the ALAT recommendations on infectious exacerbation of COPD. Arch Bronconeumol 40 7 (2004) 315-325
14. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108 Suppl. (1995) 43-52
15. Cazzola M., Salzillo A., De Giglio C., et al. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respir Med 99 6 (2005 Jun) 663-669
16. Bogaert D., van der Valk P., Ramdin R., et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 72 2 (2004 Feb) 818-823
17. Sethi S., Evans N., Grant B.J., et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347 (2002) 465-471
18. Williams C., and Masterton R. Pneumococcal immunisation in the 21st century. J Infect (2007) Novembre 1
19. Artz A.S., Ershler W.B., and Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 16 2 (2003) 308-318
20. Steentoft J., Konradsen H.B., Hilskov J., et al. Response to pneumococcal vaccine in chronic obstructive lung disease-the effect of ongoing, systemic steroid treatment. Vaccine 24 9 (2006) 1408-1412 Feb 27
21. Giebink S.G., Le C.T., Cosio F.G., et al. Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 3 Suppl (1981) S168-S178
22. Lahood N., Emerson S.S., Kumar P., et al. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 70 4 (1993 Apr) 289-294
23. Austrian R., Douglas R.M., Schiffman G., et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 89 (1976) 184-194
24. Butler J.C., Breiman R.F., Campbell J.F., et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270 15 (1993) 1826-1831
25. Cornu C., Yzebe D., Leophonte P., et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19 32 (2001) 4780-4790
26. Melegaro A., and Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 19 4 (2004) 365-375
27. Vila-Còrcoles A., Ochoa-Gondar O., Llor C., et al. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Resp J 26 6 (2005) 1086-1091
28. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 12 (2007) 2194-2212 Mar 8
29. Grijalva C.G., Nuorti J.P., and Arbogast P.G. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 9568 (2007) 1179-1186 Apr 7
30. Muscher D.M. Pneumococcal vaccine: direct and indirect effects. N Engl J Med 354 14 (2006) 1522-1524
31. Kyaw M.H., Lynfield R., Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant pneumococcus. N Engl J Med 354 14 (2006) 1455-1463
32. Hammitt L.L., Bruden D.L., Butler J.C., et al. Indirect effect of conjugate vaccine on adult carriage of streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193 11 (2006) 1487-1494 Jun 1
33. Hicks L.A., Harrison L.H., Flannery B., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 9 (2007) 1346-1354 Nov1
34. Centers for Disease Control Prevention CDC. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. Morb Mortal Wkly Rep. 56 41 (2007) 1077-1080
35. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 2 (2007 Feb) 123-128
36. NIH Bacterial Respiratory Pathogen Reference Laboratory 2007, University of Alabama-Birmingham. Available at 〈www.vaccine.uab.edu〉, [Accessed April 18, 2007].
37. Scott D.A., Komjathy S.F., and Hu B.T. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25 33 (2007) 6164-6166 Aug 14
38. Shapiro E.D., and Clemens J.D. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 101 3 (1984 Sep) 325-330
39. Dominguez A., Salleras L., Fedson D.S., et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 40 9 (2005) 1250-1257 May1
40. Evers S.M., Ament A.J., Colombo G.L., et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 26 8 (2007 Aug) 531-540
41. Sisk J.E., Moskowitz A.J., Whang W., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278 16 (1997) 1333-1339 Oct 22-29
42. Postma M.J., Heijnen M.L., and Jager J.C. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmaco econ 19 2 (2001) 215-222
43. Amazian K., Nicoloyannis N., Colin C., et al. Cost-effectiveness analysis of pneumococcal vaccination of older people in France. Med Mal Infect 32 (2002) 405-427
44. Conseil d'Evaluation des Technologies de la Santé du Quebec 1999. Cost-effectiveness and cost-utility of a pneumococcal immunization program in Quebec. CETS, Montreal, Report no. CETS 98-4RE.
45. Sisk J.E., Whang W., Butler J.C., et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 138 12 (2003) 960-968 Jun 17
46. Alfageme I., Vazquez R., Reyes N., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61 3 (2006 Mar) 189-195
47. GOLD update 2006.
48. Schoefer Y., Schaberg T., Raspe H., et al. Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases. J Infect 55 4 (2007 Oct) 347-352
49. Kohlhammer Y., Schnoor M., Schwartz M., et al. Determinants of influenza and pneumococcal vaccination in elderly people: a systematic review. Publ Health 121 10 (2007 Oct) 742-751
50. Cook I.F., Pond D., and Hartel G. Comparative reactogenicity and immunogenicity of 23-valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 25 25 (2007) 4767-4774 Jun15
51. Menzel M., Muellinger B., Weber N., et al. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 23 43 (2005) 5113-5119 Oct 17
52. Meyer P., Menzel M., Muellinger B., et al. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 24 31-32 (2006) 5832-5838 Jul 26
53. Christenson B., Hedlund J., Lundbergh P., et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Resp J 23 3 (2004) 363-368
54. Balmer P., Borrow R., and Arkwright P.D. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. Vaccine 25 34 (2007) 6321-6325 Aug 21
55. Stoehr G.A., Rose M.A., Eber S.W., et al. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 132 6 (2006 Mar) 788-790
56. Jackson L.A., Neuzil K.M., Whitney C.G., et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 23 28 (2005) 3697-3703 May 25
57. Jackson L.A., Neuzil K.M., Nahm M.H., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 25 20 (2007) 4029-4037 May16
58. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest. 2007; Sep 21 [Epub ahead of print].
59. Brueggemann A.B., Pai R., Crook D.W., et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PloS Pathog 3 11 (2007 Nov) e168
60. Pichichero M.E., and Casey J.R. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298 15 (2007) 1772-1778 Oct17
61. Muñoz-Almagro C., Jordan I., Gene A., et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46 2 (2008) 174-182
62. Morsczeck C., Prokohova T., Sigh J., et al. P. Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 14 1 (2008 Jan) 74-81
63. Bogaert D., Hermans P.W., Adrian P.V., et al. Pneumococcal vaccines: an update on current strategies. Vaccine 22 17-18 (2004) 2209-2220
64. Felmingham D., Cantón R., and Jenkins S.G. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among streptococcus pneumoniae isolates 2001-2004. J Infect 55 2 (2007) 111-118